Hongjing Xia
Principal Scientist II Novartis
Hongjing Xia is a team lead with deep expertise in cutting-edge technologies in cell and gene therapy. Her work focuses on advancing next-generation delivery platforms targeting T cells and hematopoietic stem cells (HSCs), with the goal of enabling transformative therapeutics for autoimmune disorders and sickle cell disease.
Seminars
Wednesday 8th April 2026
Targeted Delivery of Therapeutic Cargo to T Cells & HSC with Extrahepatic Tropism
9:00 am
- Antibody-Free Targeted Delivery via LNP Engineering: Our investigation into targeted delivery to T cells and hematopoietic stem cells (HSCs) using lipid nanoparticle (LNP) formulation modifications, supported by both in vitro and in vivo data, demonstrates the potential of antibody-free strategies for cell-specific mRNA delivery
- Ligand- and Antibody-Mediated Targeting Approaches: We also explored targeted delivery to T cells and HSCs using antibody or ligand conjugation methods, comparing their efficiency and specificity to non-antibody-based approaches
- Key Observations and Insights: We will share critical findings from both delivery strategies, including comparative performance, biodistribution, and implications for therapeutic applications
